Related Experiment Video

Updated: Dec 3, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.8K

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

Frits van Rhee1, Jean-François Rossi2, David Simpson3

  • 1Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

British Journal of Haematology
|October 31, 2020
PubMed
Abstract

No abstract available in PubMed .

Keywords:
multicentric Castleman diseasesiltuximab

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.5K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.6K

Related Experiment Videos

Last Updated: Dec 3, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.8K
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.5K
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K

Articles linked to this work by shared authors, journal, and citation graph.

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab.

Pediatric blood & cancer·2026

Real-World Outcomes of Tisagenlecleucel Versus Standard-of-Care Salvage Chemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Analysis From Korea.

Journal of Korean medical science·2026

Impact of Intensified Chemoimmunotherapy Regimens in Aggressive Non-Hodgkin Lymphoma on Reproduction Patterns.

European journal of haematology·2026

Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study.

JMIR research protocols·2026

First-line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma.

HemaSphere·2026

Efficacy and Safety of CAR-T Cell Therapy and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma with Renal Impairment: A Propensity Score-Matched Analysis.

Cancers·2026

SENIOR-IPI: An easily applicable prognostic index for first-line large B-cell lymphomas patients >80 years treated with curative intent.

British journal of haematology·2026

CALR-mutated myeloproliferative neoplasms: Refining molecular risk beyond the driver.

British journal of haematology·2026

RESOLVE to do better.

British journal of haematology·2026

Real-world outcomes of nivolumab-AVD and brentuximab vedotin-AVD in paediatric and adult advanced-stage Hodgkin lymphoma.

British journal of haematology·2026

Development and validation of a model for stratifying haematological malignancy risk in primary care using basic blood tests.

British journal of haematology·2026

SLIT2 modulates leukaemic cell proliferation and stromal support in acute myeloid leukaemia models.

British journal of haematology·2026

Clinical Practice Guideline: The Diagnosis, Treatment, and Follow-Up Management of Thrombotic Thrombocytopenic Purpura.

Deutsches Arzteblatt international·2026

Association Between EBV Lytic Replication and Liver Injury in Patients With HBeAg-Negative Chronic HBV Infection.

Journal of medical virology·2026

Expanded protocadherin-1 usage reveals a broader hantavirus entry landscape.

Journal of virology·2026

The Clinical Impact of End-of-Consolidation Measurable Residual Disease in High-Risk Pediatric B-Cell Acute Lymphoblastic Leukemia.

Cancer control : journal of the Moffitt Cancer Center·2026

Diagnosis-based laboratory information system flags to support specialized transfusion protocols in sickle cell disease.

Transfusion·2026

Donor Blood Management: A Complementary Framework to Patient Blood Management.

EJHaem·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us